Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study von Chari, Ajai, Rodriguez‐Otero, Paula, McCarthy, Helen, Suzuki, Kenshi, Hungria, Vania, Sureda Balari, Anna, Perrot, Aurore, Hulin, Cyrille, Magen, Hila, Iida, Shinsuke, Maisnar, Vladimir, Karlin, Lionel, Pour, Ludek, Parasrampuria, Dolly A., Masterson, Tara, Kosh, Michele, Yang, Shiyi, Delioukina, Maria, Qi, Ming, Carson, Robin, Touzeau, Cyrille

Volltext

Real‐world study on adoption of standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Ita... von Weisel, Katja, Wadlund, Astrid Ottosson, Gungor, Guntug, Dergarabetian, Eileen, Pacheco, Cécile, Masurkar, Nihar, Rodriguez‐Otero, Paula

Volltext

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study von Larocca, Alessandra, Leleu, Xavier, Touzeau, Cyrille, Bladé, Joan, Paner, Agne, Mateos, María‐Victoria, Cavo, Michele, Maisel, Christopher, Alegre, Adrían, Oriol, Albert, Raptis, Anastasios, Rodriguez‐Otero, Paula, Mazumder, Amitabha, Laubach, Jacob, Nadeem, Omar, Sandberg, Anna, Orre, Marie, Torrång, Anna, Bakker, Nicolaas A., Richardson, Paul G.

Volltext

Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/I... von Ocio, Enrique M., Motlló, Cristina, Rodríguez‐Otero, Paula, Martínez‐López, Joaquín, Cejalvo, Mª José, Martín‐Sánchez, Jesús, Bladé, Joan, García‐Malo, Mª Dolores, Dourdil, Mª Victoria, García‐Mateo, Aránzazu, Arriba, Felipe, García‐Sanz, Ramón, Rubia, Javier, Oriol, Albert, Lahuerta, Juan‐José, San‐Miguel, Jesús F., Mateos, María‐Victoria

Volltext

Epigenetic Silencing of the Tumor Suppressor MicroRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia von AGIRRE, Xabier, VILAS-ZORNOZA, Amaia, RIFON, José, BANDRES, Eva, CALASANZ, Maria José, MARTIN, Vanesa, HEINIGER, Anabel, TORRES, Antonio, SIEBERT, Reiner, ROMAN-GOMEZ, José, PROSPER, Felipe, JIMENEZ-VELASCO, Antonio, IGNACIO MARTIN-SUBERO, José, CORDEU, Lucia, GARATE, Leire, SAN JOSE-ENERIZ, Edurne, ABIZANDA, Gloria, RODRIGUEZ-OTERO, Paula, FORTES, Puri

Volltext

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics von Richardson, Paul G., Schjesvold, Fredrik, Weisel, Katja, Moreau, Philippe, Anderson, Larry D., White, Darrell, Rodriguez‐Otero, Paula, Sonneveld, Pieter, Engelhardt, Monika, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Beksac, Meral, Oriol, Albert, Lindsay, Jindriska, Liberati, Anna Marina, Galli, Monica, Robak, Pawel, Larocca, Alessandra, Yagci, Munci, Vural, Filiz, Kanate, Abraham S., Jiang, Ruiyun, Grote, Lara, Peluso, Teresa, Dimopoulos, Meletios

Volltext

Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts von Amundarain, Ane, Valcárcel, Luis V., Ordoñez, Raquel, Garate, Leire, Miranda, Estíbaliz, Cendoya, Xabier, Carrasco‐Leon, Arantxa, Calasanz, María José, Paiva, Bruno, Meydan, Cem, Mason, Christopher E., Melnick, Ari, Rodriguez‐Otero, Paula, Martín‐Subero, José I., San Miguel, Jesús, Planes, Francisco J., Prósper, Felipe, Agirre, Xabier

Volltext

Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results von Raab, Marc S, Zamagni, Elena, Manier, Salomon, Rodriguez-Otero, Paula, Schjesvold, Fredrik, Broijl, Annemiek

Volltext

Epigenetic regulation of the non‐canonical Wnt pathway in acute myeloid leukemia von Martín, Vanesa, Valencia, Ana, Agirre, Xabier, Cervera, Jose, Jose‐Eneriz, Edurne San, Vilas‐Zornoza, Amaia, Rodriguez‐Otero, Paula, Sanz, Miguel A., Herrera, Concepción, Torres, Antonio, Prosper, Felipe, Román‐Gómez, Jose

Volltext

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study von Tomasson, Michael H., Iida, Shinsuke, Niesvizky, Ruben, Mohty, Mohamad, Bahlis, Nizar J., Martinez‐Lopez, Joaquin, Koehne, Guenther, Rodriguez‐Otero, Paula, Miles Prince, H., Viqueira, Andrea, Leip, Eric, Conte, Umberto, Sullivan, Sharon T., Lesokhin, Alexander M.

Volltext

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study von Lonial, Sagar, Lee, Hans C, Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K, Chari, Ajai, Abdallah, Al-Ola, Callander, Natalie, Lendvai, Nikoletta, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Karlin, Lionel, Libby, Edward, Arnulf, Bertrand, Facon, Thierry, Hulin, Cyrille, Kortüm, K Martin, Rodríguez-Otero, Paula, Usmani, Saad Z, Hari, Parameswaran, Baz, Rachid, Quach, Hang, Moreau, Philippe, Voorhees, Peter M, Gupta, Ira, Hoos, Axel, Zhi, Eric, Baron, January, Piontek, Trisha, Lewis, Eric, Jewell, Roxanne C, Dettman, Elisha J, Popat, Rakesh, Esposti, Simona Degli, Opalinska, Joanna, Richardson, Paul, Cohen, Adam D

Volltext

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant‐ineligible Multiple Myeloma Patients von Ocio, Enrique M., Bringhen, Sara, Martinez‐Lopez, Joaquin, San‐Miguel, Jesus, Oliva, Stefania, Rodriguez‐Otero, Paula, Le Roux, Nadia, Dong, Yvonne, Doroumian, Severine, Macé, Sandrine, Mateos, Maria‐Victoria

Volltext

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma von Moreno, Laura, Perez, Cristina, Zabaleta, Aintzane, Manrique, Irene, Alignani, Diego, Ajona, Daniel, Blanco, Laura, Lasa, Marta, Maiso, Patricia, Rodriguez, Idoia, Garate, Sonia, Jelinek, Tomas, Segura, Victor, Moreno, Cristina, Merino, Juana, Rodriguez-Otero, Paula, Panizo, Carlos, Prosper, Felipe, San-Miguel, Jesus F, Paiva, Bruno

Volltext

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study von Mateos, Maria‐Victoria, Orlowski, Robert Z., Ocio, Enrique M., Rodríguez‐Otero, Paula, Reece, Donna, Moreau, Philippe, Munshi, Nikhil, Avigan, David E., Siegel, David S., Ghori, Razi, Farooqui, Mohammed Z. H., Marinello, Patricia, San-Miguel, Jesus

Volltext

P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST... von Wong, Sandy W., Bar, Noffar, Victoria Mateos, María, Ribas, Paz, Hansson, Markus, Paris, Laura, Hofmeister, Craig, Rodriguez‐Otero, Paula, Aranzazu Bermúdez, Maria, Santoro, Armando, Yee, Andrew J., Creignou, Maria, Encinas, Cristina, Cerchione, Claudio, Rubia, Javier, Oriol, Albert, Ferstl, Barbara, Besemer, Britta, Chen, Jinjie, Chung, Alexander, Boss, Isaac W., Gaudy, Allison, LI, Shaoyi, Hsu, Kevin, Godwin, Colin, Burgess, Michael R., San‐Miguel, Jesús, Jose Costa, Luciano

Volltext

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network von Ludwig, Heinz, Terpos, Evangelos, van de Donk, Niels, Mateos, Maria-Victoria, Moreau, Philippe, Dimopoulos, Melitios-Athanasios, Delforge, Michel, Rodriguez-Otero, Paula, San-Miguel, Jesús, Yong, Kwee, Gay, Francesca, Einsele, Hermann, Mina, Roberto, Caers, Jo, Driessen, Christoph, Musto, Pellegrino, Zweegman, Sonja, Engelhardt, Monika, Cook, Gordon, Weisel, Katja, Broijl, Annemiek, Beksac, Meral, Bila, Jelena, Schjesvold, Fredrik, Cavo, Michele, Hajek, Roman, Touzeau, Cyrille, Boccadoro, Mario, Sonneveld, Pieter

Volltext

CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy? von Rodriguez-Otero, Paula, Martin, Thomas

Volltext

Cellular therapy for multiple myeloma: what's now and what's next von Rodriguez-Otero, Paula, San-Miguel, Jesús F

Volltext

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma von Alegre, Adrián, Rubia, Javier, Sureda Balari, Anna, Encinas Rodríguez, Cristina, Suárez, Alexia, Blanchard, María Jesús, Bargay Lleonart, Joan, Rodríguez‐Otero, Paula, Insunza, Andrés, Palomera, Luis, Peñarrubia, María Jesús, Ríos‐Tamayo, Rafael, Casado Montero, Luis Felipe, González, Marta Sonia, Potamianou, Anna, Couturier, Catherine, Pei, Huiling, Hevia, Henar, Milionis, Iordanis, Gaudig, Maren, Mateos, María‐Victoria

Volltext

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity von Martinez-Calle, Nicolas, Rodriguez-Otero, Paula, Villar, Sara, Mejías, Luis, Melero, Ignacio, Prosper, Felipe, Marinello, Patricia, Paiva, Bruno, Idoate, Miguel, San-Miguel, Jesus

Volltext